I Want You Back: Putting The Patient Into Policy
This article was originally published in Scrip
Executive Summary
Time was when the patient barely got a look in where drug development was concerned. Pharma firms would identify a new substance with therapeutic potential in a disease like breast cancer or hypertension, develop a drug and get it approved. Patients were at the receiving end and had little or no say in how the drug was conceived, developed and evaluated. The regulators themselves had little idea of the impact their decisions and policies had on patients' everyday lives.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.